BevacizumabIn First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma

被引：0
|
作者：
James E. Frampton
Gillian M. Keating
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
BioDrugs | 2008年 / 22卷
关键词：
Vascular Endothelial Growth Factor; Renal Cell Carcinoma; Bevacizumab; Sorafenib; Erlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▴ Bevacizumab, an anti-vascular endothelial growth factor recombinant humanized monoclonal antibody, directly inhibits tumor angiogenesis and hence tumor growth.
引用
收藏
页码：113 / 120
页数：7
相关论文
共 50 条
  • [1] Bevacizumab - In first-line treatment of advanced and/or metastatic renal cell carcinoma
    Frampton, James E.
    Keating, Gillian M.
    BIODRUGS, 2008, 22 (02) : 113 - 120
  • [2] First-line treatment of metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Netsch, Christopher
    Gross, Andreas J. J.
    UROLOGIE, 2023, 62 (08): : 830 - 839
  • [3] BevacizumabIn First-Line Treatment of Metastatic Breast Cancer
    Lesley J. Scott
    Drugs, 2007, 67 : 1793 - 1799
  • [4] Optimising first-line treatment for metastatic renal cell carcinoma
    de Velasco, Guillermo
    LANCET, 2020, 395 (10219): : E7 - E7
  • [5] Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment
    Chen, Yan
    Du, Ella X.
    Sundar, Manasvi
    Betts, Keith A.
    Yin, Xin
    Eiffert, Samantha
    Beauchamp, Karen
    Delgado, Andrew
    Rosenblatt, Lisa
    PHARMACOECONOMICS-OPEN, 2025, 9 (01) : 125 - 136
  • [6] First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
    Serzan, Michael T.
    Xu, Wenxin
    Berg, Stephanie A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (05) : 951 - 964
  • [7] The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma
    Kameda, Tomohiro
    Takayama, Tatsuya
    Sugihara, Toru
    Takeshima, Saki
    Yamazaki, Masahiro
    Komatsubara, Maiko
    Kamei, Jun
    Fujisaki, Akira
    Ando, Satoshi
    Kurokawa, Shinsuke
    Fujimura, Tetsuya
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (04) : 241 - 246
  • [8] Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma
    Vitale, Maria Giuseppa
    Nasso, Cecilia
    Oltrecolli, Marco
    Baldessari, Cinzia
    Fanelli, Martina
    Dominici, Massimo
    Sabbatini, Roberto
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1183 - 1192
  • [9] New approaches to first-line treatment of advanced renal cell carcinoma
    George, Daniel J.
    Lee, Chung-Han
    Heng, Daniel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [10] Cabozantinib Approved for First-Line Treatment of Advanced Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 96 - 96
12345